BR112016004211B1 - Uso de 3-carbóxi-n-etil-n,n-dimetilpropan-1-amínio ou seus sais farmaceuticamente aceitáveis na prevenção e tratamento do diabetes - Google Patents
Uso de 3-carbóxi-n-etil-n,n-dimetilpropan-1-amínio ou seus sais farmaceuticamente aceitáveis na prevenção e tratamento do diabetes Download PDFInfo
- Publication number
- BR112016004211B1 BR112016004211B1 BR112016004211-5A BR112016004211A BR112016004211B1 BR 112016004211 B1 BR112016004211 B1 BR 112016004211B1 BR 112016004211 A BR112016004211 A BR 112016004211A BR 112016004211 B1 BR112016004211 B1 BR 112016004211B1
- Authority
- BR
- Brazil
- Prior art keywords
- carboxy
- ethyl
- dimethylpropan
- pharmaceutically acceptable
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13186201 | 2013-09-26 | ||
| EP13186201.3 | 2013-09-26 | ||
| PCT/IB2014/064514 WO2015044828A1 (en) | 2013-09-26 | 2014-09-15 | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016004211A2 BR112016004211A2 (es) | 2017-08-01 |
| BR112016004211B1 true BR112016004211B1 (pt) | 2022-09-06 |
Family
ID=49231372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016004211-5A BR112016004211B1 (pt) | 2013-09-26 | 2014-09-15 | Uso de 3-carbóxi-n-etil-n,n-dimetilpropan-1-amínio ou seus sais farmaceuticamente aceitáveis na prevenção e tratamento do diabetes |
Country Status (9)
| Country | Link |
|---|---|
| CN (1) | CN105530929B (es) |
| AR (1) | AR099638A1 (es) |
| BR (1) | BR112016004211B1 (es) |
| CA (1) | CA2924682C (es) |
| JO (1) | JO3333B1 (es) |
| MX (1) | MX368505B (es) |
| TN (1) | TN2016000064A1 (es) |
| WO (1) | WO2015044828A1 (es) |
| ZA (1) | ZA201600894B (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2067474A1 (en) * | 2007-12-05 | 2009-06-10 | Grindeks, a joint stock company | Medical use of 3-(2,2,2-trimethylhydrazinium) propionate hydrogen fumarate |
| LV14345B (lv) | 2009-10-22 | 2011-07-20 | Grindeks, A/S | 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai |
| CA2832693C (en) | 2011-04-27 | 2018-10-02 | Grindeks, A Joint Stock Company | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease |
-
2014
- 2014-08-05 JO JOP/2014/0244A patent/JO3333B1/ar active
- 2014-08-13 AR ARP140103039A patent/AR099638A1/es unknown
- 2014-09-15 CA CA2924682A patent/CA2924682C/en active Active
- 2014-09-15 TN TN2016000064A patent/TN2016000064A1/en unknown
- 2014-09-15 BR BR112016004211-5A patent/BR112016004211B1/pt active IP Right Grant
- 2014-09-15 WO PCT/IB2014/064514 patent/WO2015044828A1/en active Application Filing
- 2014-09-15 CN CN201480050485.3A patent/CN105530929B/zh active Active
- 2014-09-15 MX MX2016003347A patent/MX368505B/es active IP Right Grant
-
2016
- 2016-02-09 ZA ZA2016/00894A patent/ZA201600894B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JO3333B1 (ar) | 2019-03-13 |
| CN105530929A (zh) | 2016-04-27 |
| MX368505B (es) | 2019-10-04 |
| AR099638A1 (es) | 2016-08-10 |
| CA2924682C (en) | 2018-02-27 |
| ZA201600894B (en) | 2017-05-31 |
| TN2016000064A1 (en) | 2017-07-05 |
| MX2016003347A (es) | 2016-06-24 |
| BR112016004211A2 (es) | 2017-08-01 |
| CN105530929B (zh) | 2018-03-02 |
| CA2924682A1 (en) | 2015-04-02 |
| WO2015044828A1 (en) | 2015-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luzi et al. | Leucine metabolism in IDDM: role of insulin and substrate availability | |
| Ekelund et al. | Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology | |
| TW200838545A (en) | Therapeutic agent for painful disease | |
| ES2967693T3 (es) | Composiciones del inhibidor de la dopa descarboxilasa | |
| CN101022784A (zh) | 左旋多巴输液和注射液 | |
| US10813902B2 (en) | DOPA decarboxylase inhibitor compositions | |
| US20220288018A1 (en) | Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome | |
| BR112016004211B1 (pt) | Uso de 3-carbóxi-n-etil-n,n-dimetilpropan-1-amínio ou seus sais farmaceuticamente aceitáveis na prevenção e tratamento do diabetes | |
| Tedroff et al. | Central action of benserazide after COMT inhibition demonstrated in vivo by PET | |
| US9757354B2 (en) | Therapeutic formulations and methods | |
| Cifuentes et al. | Synchronization in the heart rate and the vasomotion in rat aorta: effect of arsenic trioxide | |
| Iezhitsa et al. | Comparative study of the efficacy of potassium magnesium L-, D-and DL-aspartate stereoisomers in overcoming digoxin-and furosemide-induced potassium and magnesium depletions | |
| EP3846779A1 (en) | Magnesium-containing formulation and uses thereof | |
| CN104447722A (zh) | 坎格列净化合物 | |
| US12042493B2 (en) | Pharmaceutical compounds for use in treating Huntington's disease | |
| ES2359910T3 (es) | Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso. | |
| AU2018210739B2 (en) | Phenylcreatine, its use and method for its production | |
| WO2020026471A1 (ja) | グルコース消費促進剤および解糖系促進剤 | |
| WO2020026570A1 (ja) | グルコース消費促進剤および解糖系促進剤 | |
| Jellinge et al. | Acetaminophen poisoning-a case report | |
| WO2007075151A1 (en) | Composite vasodilator based on a no-group donator and a promoter | |
| JP2007238613A (ja) | 非回復性睡眠のためのアルファ−デルタリガンド | |
| RU2457198C1 (ru) | Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью | |
| WO2017175859A1 (ja) | 乳酸アシドーシスの予防又は治療のための医薬 | |
| PT1773314E (pt) | Uso de l-carnitina para o tratamento de doenças cardiovasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2014, OBSERVADAS AS CONDICOES LEGAIS |